Stockscreener 앱 받기
402.90
0.10%
-0.40
시간 외 거래:
402.77
-0.13
-0.03%
전일 마감가:
$403.30
열려 있는:
$404.66
하루 거래량:
1.11M
Relative Volume:
0.64
시가총액:
$103.30B
수익:
$11.39B
순이익/손실:
$3.64B
주가수익비율:
28.80
EPS:
13.9904
순현금흐름:
$3.50B
1주 성능:
+1.92%
1개월 성능:
+1.71%
6개월 성능:
-15.11%
1년 성능:
-11.51%
1일 변동 폭
$400.74
$405.44
1주일 범위
$385.86
$411.91
52주 변동 폭
$362.50
$519.88
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
402.90 | 103.40B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.48 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
787.94 | 48.96B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
344.53 | 37.77B | 4.56B | -176.77M | 225.30M | -1.7177 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet? - Yahoo
Will Vertex Pharmaceuticals Incorporated price bounce be sustainableJuly 2025 Momentum & AI Enhanced Execution Alerts - newser.com
Published on: 2025-10-06 04:49:48 - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock remains top ratedQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
Will Vertex Pharmaceuticals Incorporated (VX1) stock outperform value peersMarket Volume Report & Free High Accuracy Swing Entry Alerts - newser.com
Is Vertex Pharmaceuticals Incorporated reversing from oversold territoryWeekly Trade Report & Precise Swing Trade Entry Alerts - newser.com
Vertex Pharmaceuticals (VRTX) Highlights Pipeline Progress at BofA Global Healthcare Conference - MSN
2 Beaten-Down Stocks Primed for a Comeback - The Motley Fool
Chart based exit strategy for Vertex Pharmaceuticals IncorporatedMarket Rally & Daily Stock Trend Watchlist - newser.com
News impact scoring models applied to Vertex Pharmaceuticals IncorporatedQuarterly Investment Review & Weekly Watchlist of Top Performers - newser.com
Can Vertex Pharmaceuticals Incorporated stock resist sector downturnsTrade Entry Summary & Breakout Confirmation Trade Signals - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock could outperform next year2025 Technical Overview & Reliable Breakout Forecasts - newser.com
NHS England to Offer Alyftrek for Cystic Fibrosis - respiratory-therapy.com
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' - Benzinga
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs? - PharmaVoice
Vertex Pharmaceuticals (VRTX): Assessing Valuation as Shares Hold Steady and Long-Term Prospects Remain Key - Yahoo Finance
Is Vertex Pharmaceuticals Incorporated (VX1) stock overpriced at current multiplesJuly 2025 Update & Free Long-Term Investment Growth Plans - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Pure Financial Advisors LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
What MACD signals say about Vertex Pharmaceuticals IncorporatedJuly 2025 Pullbacks & Low Volatility Stock Suggestions - newser.com
Published on: 2025-10-03 02:22:36 - newser.com
Published on: 2025-10-03 01:57:58 - newser.com
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News - GuruFocus
Diabetic Peripheral Neuropathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma - Barchart.com
Published on: 2025-10-01 09:22:12 - newser.com
What Does the Market Think About Vertex Pharmaceuticals Inc? - Sahm
Will Vertex Pharmaceuticals Incorporated (VX1) stock remain on Wall Street radarJuly 2025 Market Mood & Safe Entry Momentum Tips - newser.com
Lee Johnson Capital Management LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
GC Wealth Management RIA LLC Buys 1,314 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-09-30 02:36:28 - newser.com
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling - BioSpace
Is Vertex Pharmaceuticals Incorporated a good long term investmentGlobal Market Influence & Low Cost Market Tips - earlytimes.in
SWS Partners Has $1.11 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
V Square Quantitative Management LLC Buys 1,875 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
0.19%
자본화:
|
볼륨(24시간):